Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism

PHASE4RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions
Primary Hyperparathyroidism
Interventions
DRUG

Zoledronic acid 4 mg

Product name/EU MP number: Zoledronic Acid Oresund Pharma 4 mg/100 ml infusionsvätska, lösning/PRD8924813 (Test) Substance (name/ code): ZOLEDRONIC ACID/SUB00176MIG Strength: Zoledronic Acid 0.04mg Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 52486 / SE Modified in relation to MA: No Max Dosage: mg milligram(s) Duration of use: Week

DRUG

Natriumklorid 9 mg/ml, Fresenius Kabi

"Product name/EU MP number: Natriumklorid Baxter ClearFlex 9 mg/ml,infusionsvæske, opløsning/PRD456031 (Placebo) Substance (name/ code): SODIUM CHLORIDE/SUB12581MIG Strength: Sodium Chloride 0.9g / 100mL Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 32466 / DK Modified in relation to MA: No Max Dosage: ml millilitre(s) Duration of use: Week"

Trial Locations (1)

8200

RECRUITING

Aarhus University Hospital, Aarhus N

All Listed Sponsors
lead

University of Aarhus

OTHER